openPR Logo
Press release

Tyrosine Kinase 2 Inhibitors Pipeline Assessment, 2024 Updates | In-depth Insights into the Emerging Drugs, Latest FDA, EMA, and PMDA Approvals, Clinical Trials | Galapagos, Haisco Pharmaceutic

05-22-2024 03:50 PM CET | Business, Economy, Finances, Banking & Insurance

Press release from: ABNewswire

Tyrosine Kinase 2 Inhibitors Pipeline Assessment, 2024 Updates

(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Tyrosine Kinase 2 (TYK2) Inhibitors pipeline constitutes 15+ key companies continuously working towards developing 15+ Tyrosine Kinase 2 (TYK2) Inhibitors treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
The Tyrosine Kinase 2 (TYK2) Inhibitors Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

"Tyrosine Kinase 2 (TYK2) Inhibitors Pipeline Insight, 2024 [https://www.delveinsight.com/sample-request/tyk2-kinase-inhibitors-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Tyrosine Kinase 2 (TYK2) Inhibitors Market.

Some of the key takeaways from the Tyrosine Kinase 2 (TYK2) Inhibitors Pipeline Report:

*
Companies across the globe are diligently working toward developing novel Tyrosine Kinase 2 (TYK2) Inhibitors treatment therapies with a considerable amount of success over the years.

*
Tyrosine Kinase 2 (TYK2) Inhibitors companies working in the treatment market are Sudo Biosciences, Sareum Holdings PLC, Galapagos NV, Ventyx Biosciences, Nimbus Therapeutics, Bristol-Myers Squibb, Priovant Therapeutics, and others, are developing therapies for the Tyrosine Kinase 2 (TYK2) Inhibitors treatment

*
Emerging Tyrosine Kinase 2 (TYK2) Inhibitors therapies in the different phases of clinical trials are- TYK2 Inhibitors, SDC-1801, GLPG3667, VTX958, NDI-034858, Sotyktu, Brepocitinib, and others are expected to have a significant impact on the Tyrosine Kinase 2 (TYK2) Inhibitors market in the coming years.

*
In March 2024, Alumis Inc., a biopharmaceutical company in the clinical stage, specializing in oral therapies tailored to address immune-mediated conditions, unveiled encouraging clinical findings from a Phase 2 trial of ESK-001. This innovative compound is a meticulously targeted allosteric inhibitor of tyrosine kinase 2 (TYK2), showing promise in treating individuals grappling with moderate-to-severe plaque psoriasis.

*
In July 2023, InnoCare Pharma administered the first dose of ICP-488, a tyrosine kinase 2 (TYK2) JH2 allosteric inhibitor, to a patient in a clinical trial in China aimed at treating psoriasis. The study seeks to evaluate the efficacy and safety of this treatment in individuals with moderate-to-severe psoriasis, a persistent immune-mediated condition.

*
In June 2022, Roivant Sciences and Pfizer revealed the launch of Priovant Therapeutics, a specialized company focused on creating and marketing innovative treatments for autoimmune diseases that pose significant health risks. Priovant was formed in September 2021 as a result of an agreement between Roivant and Pfizer. Under this arrangement, Pfizer granted Priovant the global development rights for oral and topical Brepocitinib, along with commercial rights in the United States and Japan. Pfizer retains a 25% equity stake in Priovant.

Tyrosine Kinase 2 (TYK2) Inhibitors Overview

Tyrosine kinase 2 (TYK2) inhibitors are a class of pharmaceutical compounds designed to inhibit the activity of the TYK2 enzyme. TYK2 is a member of the Janus kinase (JAK) family of enzymes, which play a crucial role in signal transduction pathways involved in immune responses and inflammation. In particular, TYK2 is involved in the signaling of cytokines, which are proteins that regulate various immune and inflammatory processes.

Get a Free Sample PDF Report to know more about Tyrosine Kinase 2 (TYK2) Inhibitors Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/tyk2-kinase-inhibitors-pipeline-insight [https://www.delveinsight.com/report-store/tyk2-kinase-inhibitors-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Emerging Tyrosine Kinase 2 (TYK2) Inhibitors Drugs Under Different Phases of Clinical Development Include:

*
TYK2 Inhibitors: Sudo Biosciences

*
SDC-1801: Sareum Holdings PLC

*
GLPG3667: Galapagos NV

*
VTX958: Ventyx Biosciences

*
NDI-034858: Nimbus Therapeutics

*
Sotyktu: Bristol-Myers Squibb

*
Brepocitinib: Priovant Therapeutics

Tyrosine Kinase 2 (TYK2) Inhibitors Route of Administration

Tyrosine Kinase 2 (TYK2) Inhibitors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as

*
Infusion

*
Intradermal

*
Intramuscular

*
Intranasal

*
Intravaginal

*
Oral

*
Parenteral

*
Subcutaneous

*
Topical

*
Molecule Type

Tyrosine Kinase 2 (TYK2) Inhibitors Molecule Type

Tyrosine Kinase 2 (TYK2) Inhibitors Products have been categorized under various Molecule types, such as

*
Vaccines

*
Monoclonal Antibody

*
Peptides

*
Polymer

*
Small molecule

*
Product Type

Tyrosine Kinase 2 (TYK2) Inhibitors Pipeline Therapeutics Assessment

*
Tyrosine Kinase 2 (TYK2) Inhibitors Assessment by Product Type

*
Tyrosine Kinase 2 (TYK2) Inhibitors By Stage and Product Type

*
Tyrosine Kinase 2 (TYK2) Inhibitors Assessment by Route of Administration

*
Tyrosine Kinase 2 (TYK2) Inhibitors By Stage and Route of Administration

*
Tyrosine Kinase 2 (TYK2) Inhibitors Assessment by Molecule Type

*
Tyrosine Kinase 2 (TYK2) Inhibitors by Stage and Molecule Type

DelveInsight's Tyrosine Kinase 2 (TYK2) Inhibitors Report covers around 15+ products under different phases of clinical development like

*
Late-stage products (Phase III)

*
Mid-stage products (Phase II)

*
Early-stage product (Phase I)

*
Pre-clinical and Discovery stage candidates

*
Discontinued & Inactive candidates

*
Route of Administration

Further Tyrosine Kinase 2 (TYK2) Inhibitors product details are provided in the report. Download the Tyrosine Kinase 2 (TYK2) Inhibitors pipeline report to learn more about the emerging Tyrosine Kinase 2 (TYK2) Inhibitors therapies [https://www.delveinsight.com/sample-request/tyk2-kinase-inhibitors-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Some of the key companies in the Tyrosine Kinase 2 (TYK2) Inhibitors Therapeutics Market include:

Key companies developing therapies for Tyrosine Kinase 2 (TYK2) Inhibitors are - Galapagos, Haisco Pharmaceutical Group, Sareum, Oncostellae, Incyte Corporation, Bristol-Myers Squibb, Oncostellae, Pfizer, and others.

Tyrosine Kinase 2 (TYK2) Inhibitors Pipeline Analysis:

The Tyrosine Kinase 2 (TYK2) Inhibitors pipeline report provides insights into

*
The report provides detailed insights about companies that are developing therapies for the treatment of Tyrosine Kinase 2 (TYK2) Inhibitors with aggregate therapies developed by each company for the same.

*
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Tyrosine Kinase 2 (TYK2) Inhibitors Treatment.

*
Tyrosine Kinase 2 (TYK2) Inhibitors key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

*
Tyrosine Kinase 2 (TYK2) Inhibitors Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.

*
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Tyrosine Kinase 2 (TYK2) Inhibitors market.

The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Tyrosine Kinase 2 (TYK2) Inhibitors drugs and therapies [https://www.delveinsight.com/sample-request/tyk2-kinase-inhibitors-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Tyrosine Kinase 2 (TYK2) Inhibitors Pipeline Market Drivers

*
Rise in the global prevalence of autoimmune disorders, huge investment in the R&D activities, technological advancements and innovations are some of the important factors that are fueling the Tyrosine Kinase 2 (TYK2) Inhibitors Market.

Tyrosine Kinase 2 (TYK2) Inhibitors Pipeline Market Barriers

*
However, adverse reactions induced by TYK2 inhibitors such as gastrointestinal infections, high development costs can lead to high prices of the drug in the market and other factors are creating obstacles in the Tyrosine Kinase 2 (TYK2) Inhibitors Market growth.

Scope of Tyrosine Kinase 2 (TYK2) Inhibitors Pipeline Drug Insight

*
Coverage: Global

*
Key Tyrosine Kinase 2 (TYK2) Inhibitors Companies: Sudo Biosciences, Sareum Holdings PLC, Galapagos NV, Ventyx Biosciences, Nimbus Therapeutics, Bristol-Myers Squibb, Priovant Therapeutics, and others

*
Key Tyrosine Kinase 2 (TYK2) Inhibitors Therapies: TYK2 Inhibitors, SDC-1801, GLPG3667, VTX958, NDI-034858, Sotyktu, Brepocitinib, and others

*
Tyrosine Kinase 2 (TYK2) Inhibitors Therapeutic Assessment: Tyrosine Kinase 2 (TYK2) Inhibitors current marketed and Tyrosine Kinase 2 (TYK2) Inhibitors emerging therapies

*
Tyrosine Kinase 2 (TYK2) Inhibitors Market Dynamics: Tyrosine Kinase 2 (TYK2) Inhibitors market drivers and Tyrosine Kinase 2 (TYK2) Inhibitors market barriers

Request for Sample PDF Report for Tyrosine Kinase 2 (TYK2) Inhibitors Pipeline Assessment and clinical trials [https://www.delveinsight.com/sample-request/tyk2-kinase-inhibitors-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Table of Contents

1. Tyrosine Kinase 2 (TYK2) Inhibitors Report Introduction

2. Tyrosine Kinase 2 (TYK2) Inhibitors Executive Summary

3. Tyrosine Kinase 2 (TYK2) Inhibitors Overview

4. Tyrosine Kinase 2 (TYK2) Inhibitors- Analytical Perspective In-depth Commercial Assessment

5. Tyrosine Kinase 2 (TYK2) Inhibitors Pipeline Therapeutics

6. Tyrosine Kinase 2 (TYK2) Inhibitors Late Stage Products (Phase II/III)

7. Tyrosine Kinase 2 (TYK2) Inhibitors Mid Stage Products (Phase II)

8. Tyrosine Kinase 2 (TYK2) Inhibitors Early Stage Products (Phase I)

9. Tyrosine Kinase 2 (TYK2) Inhibitors Preclinical Stage Products

10. Tyrosine Kinase 2 (TYK2) Inhibitors Therapeutics Assessment

11. Tyrosine Kinase 2 (TYK2) Inhibitors Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Tyrosine Kinase 2 (TYK2) Inhibitors Key Companies

14. Tyrosine Kinase 2 (TYK2) Inhibitors Key Products

15. Tyrosine Kinase 2 (TYK2) Inhibitors Unmet Needs

16 . Tyrosine Kinase 2 (TYK2) Inhibitors Market Drivers and Barriers

17. Tyrosine Kinase 2 (TYK2) Inhibitors Future Perspectives and Conclusion

18. Tyrosine Kinase 2 (TYK2) Inhibitors Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=tyrosine-kinase-2-inhibitors-pipeline-assessment-2024-updates-indepth-insights-into-the-emerging-drugs-latest-fda-ema-and-pmda-approvals-clinical-trials-galapagos-haisco-pharmaceutic]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV 89107
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services



This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Tyrosine Kinase 2 Inhibitors Pipeline Assessment, 2024 Updates | In-depth Insights into the Emerging Drugs, Latest FDA, EMA, and PMDA Approvals, Clinical Trials | Galapagos, Haisco Pharmaceutic here

News-ID: 3508548 • Views:

More Releases from ABNewswire

Food Preservatives Market Size, Share, Growth Opportunities, Top Manufacturers, Trends, Key Segments, and Forecast to 2028
Food Preservatives Market Size, Share, Growth Opportunities, Top Manufacturers, …
Food Preservatives Market by Function (Antimicrobials, Antioxidants), Type (Synthetic Preservatives and Natural Preservatives), Application, and Region ( North America, Europe, Asia-Pacific, Middle-East Africa) - Global Forecast to 2028 The [https://www.prnewswire.com/news-releases/food-preservatives-market-worth-3-9-billion-by-2028--exclusive-report-by-marketsandmarkets-301791539.html] was valued at US$ 3.3 billion in 2022 and is poised to grow from US$ 3.4 billion in 2023 to US$ 3.9 billion by 2028, growing at a CAGR of 3.0% in the forecast period (2023-2028). Food preservatives are substances added
Enteric Disease Testing Market Size, Share, Growth Opportunities, Top Manufacturers, Trends, Key Segments, and Forecast to 2026
Enteric Disease Testing Market Size, Share, Growth Opportunities, Top Manufactur …
Enteric Disease Testing Market by Technology (Traditional and Rapid), End Use (Food (Meat, Poultry, Seafood, Dairy, Processed Foods, and Fruits & Vegetables) and Water), Pathogen Tested, and Region - Global Forecast to 2026 The [https://www.prnewswire.com/news-releases/enteric-disease-testing-market-worth-2-4-billion-by-2026--exclusive-report-by-marketsandmarkets-301363434.html] is estimated to be USD 1.8 billion in 2021; it is projected to grow at a CAGR of 6.0% to reach USD 2.4 billion by 2026. The growth in the enteric disease testing market is attributed
$99 New Patient Special for Las Vegas Children's Dentist Services
$99 New Patient Special for Las Vegas Children's Dentist Services
Desert Kids Dental, a leading provider of pediatric dental care in Las Vegas, is thrilled to announce an exclusive $99 New Patient Special. Desert Kids Dental, a leading provider of pediatric dental care in Las Vegas, is thrilled to announce an exclusive $99 New Patient Special. This offer is designed to provide families with affordable access to top-quality dental care for their children. The special includes a thorough cleaning, comprehensive exam,
Albert Jaskula's Book,
Albert Jaskula's Book, "The Fall," Continues to Enjoy Widespread Acclaim for its …
At its release, the author might not have envisaged the book's success but after many book tours and awards, Albert Jaskula can look back with a smile for producing an exceptional piece of art Albert Jaskula released "The Fall" last year and the book has gone on to be an incredible success. When the book was first published, Albert probably never thought the book would garner as much attention and popularity

All 5 Releases


More Releases for TYK2

Non Receptor Tyrosine Protein Kinase TYK2 Market 2020 to 2026 | Top Companies Ar …
Non Receptor Tyrosine Protein Kinase TYK2 Market Report offers an industry-wide analysis of the market, including precise assessment of the demand for the Non Receptor Tyrosine Protein Kinase TYK2 Market and accurate market insights that allow readers to identify the existing opportunities and threats and optimize their investments. It offers the global sector across key regional markets and gives an extensive investigation and statistical analysis of vital market elements. The study
Frontier Pharma-Orphan and Rare Dermatological Diseases-First-in-Class Therapies …
Frontier Pharma: Orphan and Rare Dermatological Diseases-First-in-Class Therapies Demonstrate Potential Disease-Modifying Effects in Areas of High Unmet Need Such as Epidermolysis Bullosa Summary Orphan and rare dermatological diseases are considerably diverse in terms of pathophysiology, clinical presentation and disease severity. Many of these conditions are extremely debilitating and can even be life-threatening in some cases. Disease visibility can also have a profoundly negative impact on patient confidence. Unmet need within the orphan and
Janus Kinase (JAK) Inhibitors Pipeline to Witness Significant Growth due to Posi …
JAK comprises four receptors JAK1, JAK2, JAK3, and tyrosine kinase 2 (TYK2) which help in cytokine mediated signaling through the JAK/STAT pathway. There are two nearly identical phosphate transferring domains present in JAKs. The first domain demonstrates kinase activity while the other regulates the activity of the first via negative inhibition. The mutations in the JAK/STAT pathway leads to different medical conditions. Download the sample report: https://www.pharmaproff.com/request-sample/1216 The JAK inhibitors work by
Tyrosine Kinase JAK Inhibitors Market Pegged for Robust Expansion by 2026
Tyrosine kinases are enzymes capable of transferring the phosphate group from ATP (adenosine triphosphate) to a cellular protein. They function as an on or off switch for several cellular mechanisms. On the protein, the phosphate group is affiliated to the tyrosine amino acid. Tyrosine kinases are a subclass of the larger group of protein kinases that connect phosphate groups to extra amino acids (threonine and serine). In interconnecting signals in
Chondroitin Sulfate Market share forecast to witness considerable growth by anal …
The examination is a blend of essential and auxiliary research. Essential research shaped the main part of our examination endeavors alongside data gathered from telephonic meetings and connections by means of messages. Optional research included investigation of organization sites, yearly reports, official statements, stock examination introductions, and different universal and national databases. On the basis of product, this report displays the production, revenue, price, market share and growth rate of each
Global Non Receptor Tyrosine Protein Kinase TYK2 Market Analysis, Growth & Forec …
A fresh report has been added to the wide database of Market Research Hub (MRH) titled “Global Non Receptor Tyrosine Protein Kinase TYK2 Market Research Report (2017-2021)” which provides an outlook of current non receptor tyrosine protein kinase TYK2 sales market value and the expected forecast on Rate on Investment (ROI) with growing CAGR of XX% by the end of 2022. The report also studies the market worldwide, especially in